BOSTON–(BUSINESS WIRE)–AVAVA, a leader in transformative energy-based technology, today announced the appointment of Clint Carnell as Executive Chairman of the Board and Mary Fisher to its Board of Directors. These distinguished industry veterans bring a wealth of experience in scaling high-growth companies, reinforcing AVAVA’s commitment to accelerated expansion and increased market share in the medical aesthetics sector.
“We are thrilled to welcome Clint and Mary to our Board of Directors,” said Irina Erenburg, PhD, Co-Founder, CEO, and Board Member of AVAVA. “Their proven expertise in driving company growth and enhancing shareholder value will be instrumental as we pioneer a new category in medical aesthetics. With boundless energy and fearless vision, we are redefining what’s possible with innovative technology.”
Clint Carnell is a visionary executive with over two decades of leadership in the medical aesthetics industry. As CEO of The HydraFacial Company (now BeautyHealth), he led the company’s global expansion and successfully took it public, achieving significant returns for investors. Carnell currently serves as CEO of InBrace, an innovative dental aesthetics company, and is the founder of Greyspace Holdings, a boutique advisory firm. His strategic insight will be instrumental as AVAVA prepares for its next phase of growth.
“I am excited to join AVAVA as Executive Chairman,” said Carnell. “AVAVA’s groundbreaking Focal Point Technology™ has the potential to disrupt the energy-based device market like never before. I look forward to working with the team to drive growth, innovate, and create significant value for our shareholders.”
Mary Fisher brings over 30 years of pharmaceutical and biotechnology experience. As former CEO of SkinMedica Inc., she led the company through substantial growth, culminating in its acquisition by Allergan, Inc. Fisher currently serves as Chair and CEO at Colorescience and is on the Board of Directors of Dermata Therapeutics. Her expertise in brand building, strategic innovation and corporate governance will bolster AVAVA’s efforts to scale effectively.
Carnell and Fisher join AVAVA’s team of talent spanning medical innovation, business and operational excellence, including Dan Browne (AVAVA Board Member, GALDERMA Board Member, Chairman of the Board, Rythera Therapeutics, Inc., and Co-Founder, prior President & CEO of REVANCE), Irina Erenburg, PhD (AVAVA Co-Founder, CEO and Board Member), Dr. R. Rox Anderson, MD (AVAVA Co-Founder and Director of the Wellman Center of Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School), Dieter Manstein, MD, PhD (AVAVA Co-Founder and Physician Investigator, Assistant Professor, The Cutaneous Biology Research Center in the Department of Dermatology at Massachusetts General Hospital), and Henry H.L. Chan, MD, PhD, FRCP (AVAVA Co-Founder, Honorary Clinical Professor, Department of Medicine, The University of Hong Kong and Visiting Scientist of the Wellman Center for Photomedicine, Massachusetts General Hospital).
For more information, visit www.avavaskin.com.
ABOUT AVAVA
AVAVA™ is a trailblazer in energy-based technology, redefining how energy is delivered. Powered by our Focal Point Technology™, AVAVA has pioneered a new approach to energy disbursement, offering unmatched precision and unlocking new possibilities in medical aesthetics. Dedicated to advancing science, AVAVA builds on a legacy of industry innovation to create technologies that benefit all skin tones and types. Bridging science and care, AVAVA delivers energy with purpose and impact. With fearless vision and boundless energy, AVAVA is shaping the next generation of aesthetic technologies. For more information, visit www.avavaskin.com.
